ANGO
AngioDynamics, Inc.
ANGO has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ANGO overall, supported by stronger fundamentals and stronger modeled upside.
ANGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Strong |
ANGO's balance sheet is currently strong, and its revenue and cash flow are stable, but its profitability is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ANGO PE Valuation
ANGO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ANGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect ANGO's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ANGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.79 | -$0.01 |
| Q2 2026 | -$0.88 | -$0.05 |
| Q1 2026 | -$0.75 | +$0.28 |
| Q4 2025 | -$0.67 | +$4.92 |
| Q3 2025 | -$0.78 | +$5.27 |
| Q2 2025 | -$0.83 | +$3.76 |
| Q1 2025 | -$1.03 | +$3.76 |
| Q4 2024 | -$5.59 | -$5.23 |
ANGO is still losing money, but far less than before: $0.79 per share over the past year, against $6.05 at its worst in mid-2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ANGO on earnings quality, reporting a profit while its opponent remains loss making.
ANGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $80.9M | +6.9% |
| Q2 2026 | $86.6M | +8% |
| Q1 2026 | $78.4M | +8.9% |
| Q4 2025 | $79.4M | +9% |
| Q3 2025 | $75.7M | +12% |
| Q2 2025 | $80.2M | +13% |
| Q1 2025 | $72M | -4.2% |
| Q4 2024 | $72.8M | -7.9% |
ANGO's revenue has grown year over year for six quarters in a row: $81M last quarter, up 6.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9% | +5.1 points |
| Q2 2026 | -12% | -4.5 points |
| Q1 2026 | -17% | -2.7 points |
| Q4 2025 | -7.7% | +7.5 points |
| Q3 2025 | -14% | +5.3 points |
| Q2 2025 | -7.2% | +13 points |
| Q1 2025 | -14% | +252 points |
| Q4 2024 | -15% | +1.4 points |
ANGO's operating margin was −9% last quarter, up 5.1 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ANGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ANGO on profitability, with a higher operating margin.
ANGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.7M | +$936K |
| Q2 2026 | $17M | -5.5% |
| Q1 2026 | -$4.1M | +$10.8M |
| Q4 2025 | $4.2M | +153% |
| Q3 2025 | -$16.6M | +$2.7M |
| Q2 2025 | $18M | +307% |
| Q1 2025 | -$15M | -$1.8M |
| Q4 2024 | $1.7M | -64% |
ANGO's free cash flow has turned positive after two years mostly in the red: $1M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ANGO on cash flow, with more consistent year-over-year improvement.
ANGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +496K shares |
| 1 year | +2.1% | +848K shares |
| 3 years | +5.1% | +2.1M shares |
| 5 years | +8.5% | +3.3M shares |
| Available history | +11% | +4M shares |
ANGO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $1.1M |
| Q3 2024 | $552,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ANGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -2.9x | Net Cash |
| Q3 2023 | -2.1x | Net Cash |
| Q2 2022 | -32.8x | Net Cash |
| Q4 2019 | -6.1x | Net Cash |
ANGO has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ANGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 22.6 | Neutral |
ANGO's weekly RSI is 43 (neutral) and its Stochastic is 23 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ANGO PE vs Healthcare Sector
| Metric | ANGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANGO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ANGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 5.5% below |
| 20 week MA | $13.9 | 14% below |
| 50 week MA | $12.4 | 3.4% below |
| 100 week MA | $11.3 | 5.7% above |
| 200 week MA | $9.60 | 25% above |
ANGO has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 25% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ANGO on trend strength, trading above more of its moving averages.
ANGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.0 | $14.1 | -11% |
| 2021 | $14.1 | $28.2 | +100% |
| 2022 | $28.2 | $13.3 | -53% |
| 2023 | $13.3 | $7.84 | -41% |
| 2024 | $7.84 | $8.91 | +14% |
| 2025 | $8.91 | $13.1 | +47% |
| 2026 YTD | $13.1 | $12.0 | -8.5% |
ANGO has finished lower in three of the last six years. It's down 8.5% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ANGO on returns for 2026, with the stronger performance.